Comparison of second-line quadruple therapies with or without bismuth for Helicobacter pylori infection

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Jheng, Guang Hong ^a,b   Wu, I Chen ^a,c,d   Shih, Hsiang Yao ^e   Wu, Meng Chieh ^e   Kuo, Fu Chen ^f   Hu, Huang Ming ^a,c,d   Liu, Chung Jung ^a,c   Hsu, Wen Hung ^a,c,d   Hu, Chi Tan ^g   Bair, Ming Jong ^h   Kuo, Chao Hung ^a,c,d,i   Wu, Deng Chyang ^a,c,d,e   Hsu, Ping I ^j  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b Department of Internal Medicine Kaohsiung Municipal United Hospital ^*  (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

^g TZU CHI UNIVERSITY   (Taiwan)

^h MACKAY MEMORIAL HOSPITAL   (Taiwan)

ⁱ Department of Pathology   (Taiwan)

^j NATIONAL YANG MING UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; METRONIDAZOLE; RABEPRAZOLE; TETRACYCLINE; BISMUTH;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BACTERIAL CLEARANCE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HELICOBACTER INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING; AGED; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY;

HELICOBACTER PYLORI;

ADULT; AGED; AMOXICILLIN; BISMUTH; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; RABEPRAZOLE; TETRACYCLINE;

EID: 84930936210     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/163960     Document Type: Article

References (29)

1. K. E. L.McColl, "Clinical practice. Helicobacter pylori infection," The New England Journal of Medicine, vol. 362, no. 17, pp. 1597-1604, 2010.
2. P. I. Hsu, D. C. Wu, W. C. Chen et al., "Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection," Antimicrobial Agents and Chemotherapy, vol. 58, no. 10, pp. 5936-5942, 2014.
3. C.-H. Kuo, H.-M. Hu, F.-C. Kuo et al., "Efficacy of levofloxacinbased rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial," Journal of Antimicrobial Chemotherapy, vol. 63, no. 5, pp. 1017-1024, 2009.
4. M. Sasaki, N. Ogasawara, K. Utsumi et al., "Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin," Journal of Clinical Biochemistry and Nutrition, vol. 47, no. 1, pp. 53-58, 2010.
5. D. Y. Graham and L. Fischbach, "Helicobacter pylori treatment in the era of increasing antibiotic resistance," Gut, vol. 59, no. 8, pp. 1143-1153, 2010.
6. A. Tursi,W. Elisei, G.Giorgetti, M. Picchio, and G. Brandimarte, "Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study," Panminerva Medica, vol. 56, no. 1, pp. 57-61, 2014.
7. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., "Management of Helicobacter pylori infection - the Maastricht IV/Florence consensus report," Gut, vol. 61, no. 5, pp. 646-664, 2012.
8. L. G. Coelho, I.Maguinilk, S. Zaterka, J. M. Parente, M. D. C. F. Passos, and J. P. P.Moraes-Filho, "3rd Brazilian consensus on Helicobacter pylori," Arquivos de Gastroenterologia, vol. 50, no. 2, pp. 1-17, 2013.
9. A. S. Essa, J. R. Kramer, D. Y. Graham, and G. Treiber, "Metaanalysis: four-drug, three-antibiotic, non-bismuth-containing 'concomitant therapy' versus triple therapy for Helicobacter pylori eradication," Helicobacter, vol. 14, no. 2, pp. 109-118, 2009.
10. M. Okada, K. Oki, T. Shirotani et al., "A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate," Journal of Gastroenterology, vol. 33, no. 5, pp. 640-645, 1998.
11. G. Treiber, S. Ammon, E. Schneider, and U. Klotz, "Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication," Helicobacter, vol. 3, no. 1, pp. 54-58, 1998.
12. C. H. Kuo, P. I. Hsu, F. C. Kuo et al., "Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line helicobacter pylori therapy: a randomized controlled trial," Journal of Antimicrobial Chemotherapy, vol. 68, no. 1, pp. 222-228, 2013.
13. C.-H. Chi, C.-Y. Lin, B.-S. Sheu, H.-B. Yang, A.-H. Huang, and J.-J. Wu, "Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori," Alimentary Pharmacology and Therapeutics, vol. 18, no. 3, pp. 347-353, 2003.
14. D.-C. Wu, P.-I. Hsu, H.-H. Tseng et al., "Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies," Medicine, vol. 90, no. 3, pp. 180-185, 2011.
15. J. P. Gisbert and X. Calvet, "Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori," Clinical and Experimental Gastroenterology, vol. 5, no. 1, pp. 23-34, 2012.
16. B. H. Lee, N. Kim, T. J. Hwang et al., "Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea," Helicobacter, vol. 15, no. 1, pp. 38-45, 2010.
17. A. Kadayifçi, A.Uygun, Z. Polat et al., "Comparison of bismuthcontaining quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori," The Turkish Journal of Gastroenterology, vol. 23, no. 1, pp. 8-13, 2012.
18. J. Y. Moon, G. H. Kim, H. S. You et al., "Levofloxacin, metronidazole, and lansoprazole triple therapy compared to quadruple therapy as a second-line treatment of Helicobacter pylori infection in Korea," Gut and Liver, vol. 7, no. 4, pp. 406-410, 2013.
19. J.-W. Chung, J. H. Lee, H.-Y. Jung et al., "Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy," Helicobacter, vol. 16, no. 4, pp. 289-294, 2011.
20. J.-C. Yang, C.-W. Lu, and C.-J. Lin, "Treatment of Helicobacter pylori infection: current status and future concepts," World Journal of Gastroenterology, vol. 20, no. 18, pp. 5283-5293, 2014.
21. V. de Francesco, F. Giorgio, C. Hassan et al., "Worldwide H. pylori antibiotic resistance: a systematic review," Journal of Gastrointestinal and Liver Diseases, vol. 19, no. 4, pp. 409-414, 2010.
22. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, "Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin andmetronidazole added as a quadruple (hybrid) therapy for the final 7 days," Helicobacter, vol. 16, no. 2, pp. 139-145, 2011.
23. D.C.Wu, P. I. Hsu, J. Y. Wu et al., "Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection," Clinical Gastroenterology and Hepatology, vol. 8, no. 1, pp. 36.e1-41.e1, 2010.
24. W.-L. Chang, B.-S. Sheu, H.-C. Cheng, Y.-J. Yang, H.-B. Yang, and J.-J.Wu, "Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan," Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 1230-1235, 2009.
25. P. H. Katelaris, G. M. Forbes, N. J. Talley, and B. Crotty, "A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: theQUADRATE Study," Gastroenterology, vol. 123, no. 6, pp. 1763-1769, 2002.
26. M. Song and T. L. Ang, "Second and third line treatment options for Helicobacter pylori eradication," World Journal of Gastroenterology, vol. 20, no. 6, pp. 1517-1528, 2014.
27. C.-H. Kuo, S. S. W. Wang,W.-H. Hsu et al., "Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy," Helicobacter, vol. 15, no. 4, pp. 265-272, 2010.
28. T.-S. Wu, H.-M. Hu, F.-C. Kuo, and C.-H. Kuo, "Eradication of Helicobacter pylori infection," Kaohsiung Journal of Medical Sciences, vol. 30, no. 4, pp. 167-172, 2014.
29. A. C. Ford, P. Malfertheiner, M. Giguère, J. Santana, M. Khan, and P. Moayyedi, "Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and metaanalysis," World Journal of Gastroenterology, vol. 14, no. 48, pp. 7361-7370, 2008.